TY - JOUR T1 - The promoter polymorphism -1562C/T in matrix metalloproteinase-9 and COPD severity JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW SP - 230 LP - 232 DO - 10.1183/09059180.00010131 VL - 15 IS - 101 AU - D. G. Yanbaeva AU - G. F. Korytina AU - L. Z. Akhmadishina AU - S. Z. Zagidullin AU - T. V. Victorova Y1 - 2006/12/01 UR - http://err.ersjournals.com/content/15/101/230.abstract N2 - Chronic obstructive pulmonary disease (COPD) is a complex heterogeneous respiratory disease. COPD is characterized by a progressive irreversible airflow limitation that is due to a loss of lung elasticity resulting from peripheral airflow obstruction (chronic bronchitis) and parenchymal destruction (emphysema). Matrix metalloproteinases (MMP) are a major group of proteases known to regulate extracellular matrix turnover. They have been suggested to be important in the process of lung diseases associated with tissue remodeling. Polymorphisms in MMPs which known to upregulate their activity may result in the degradation of a lung matrix. A case-control study was performed to investigate the association of polymorphisms of MMP type 1 (-1607G/GG), 9 (-1562C/T) and 12 (-82A/G) genes with COPD and disease severity. A total of 309 COPD patients admitted to departments of respiratory medicine have been recruited in Ufa city hospitals (## 13, 21, and 22). COPD patients have been undergone a spirometry and a physical examination by a chest physician to refer the GOLD II-IV stages. The control group comprised of 305 healthy subjects without evidence of chronic diseases (Table Basic characteristic of study groups). ER -